Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic interaction between single nucleotide polymorphisms (SNPs). The goal is to...
Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.
After more than a decade of work, UC Irvine chemists have created a way to clearly identify...
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment. A new study¹ by Vahakn Shahinian and Yong-Fang Kuo from the Universities of Michigan and Texas...
A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk assessment when patients are first diagnosed, can also aid in determining which men are...
A new design of screening could improve ratio between benefit and harms of screening Focusing prostate cancer testing on men at highest risk of developing the disease is likely to improve the ratio between benefits and the harms of screening, suggests a paper published this week on bmj.com...
Shared-decision making, clear patient preference recommended before PSA testing Men between the ages of 50 and 69 should discuss the limited benefits and substantial harms of the prostate-specific antigen (PSA) test with their doctor before undergoing screening for prostate cancer, according to...
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through...
Research on promising new therapies and data on the relative benefits of established treatments for genitourinary cancers were released, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 14-16, 2013, at the Rosen Shingle Creek in Orlando, FL...
More...
In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic "signatures" across all metastatic tumors in each patient. The discovery of the stable, epigenetic "marks" that sit on the nuclear DNA of cancer cells and...
Analysis of 2 Years of Additional Data on Dutasteride Treatment Reported in The Journal of Urology® The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI)...
A small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, with some saying that it interfered with intimate relationships and caused them to regret the type of treatment they chose. Complaints were more common in men treated with radical...
Researchers at the Mayo Clinic in Florida have discovered that an enzyme called PRSS3, or mesotrypsin, may help drive aggressive prostate cancer. Although they don't believe it is the only factor, they suggest it offers a new target for treatment, and have themselves developed a prototype...
A drug already set to transform care for men with advanced prostate cancer has impressive benefits for men with earlier-stage disease too, a major new clinical trial shows. Abiraterone, discovered at The Institute of Cancer Research, London*, was approved last May by NICE for use on the NHS to...
Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study presented at the North Central Section of the American Urological Association's annual meeting in Chicago. Mayo Clinic urologists also discussed...
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with...
Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells. The study was...
New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress...
Research from the University of Southern California (USC) and Cancer Prevention Institute of California (CPIC) found that cooking red meats at high temperatures, especially pan-fried red meats, may increase the risk of advanced prostate cancer by as much as 40 percent. Mariana Stern, associate...
Results of a phase III clinical trial of the drug Enzalutamide, published recently in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer. "This is a major advance. Not only do we see more survival benefit than...